Introduction: Cancer-associated fibroblasts (CAFs) are an essential component of carcinogenesis. The biological origins of CAFs in humans depend on the histotype of the tumour and the region where it first originated, and thus CAFs could be derived from many different cell types. Normal fibroblasts (NFs) are abundant in the endometrium and are highly susceptible to transdifferentiation to CAFs through TGF-β activation. This study aims to identify the cell markers present in the TGF-β signalling pathways for the transition of NFs to CAFs in endometrial cancer (EC). Methods: EC will be chemically induced in ICR (Institute of Cancer Research) mice with N-methyl-N-nitrosourea (MNU) and a 17β-estradiol (E2) diet. Cancer progression will be monitored using magnetic resonance imaging (MRI) at a field of 4.7 T. CAFs will then be isolated from the TME using PDGFRα as the cell marker. Immunohistochemistry (IHC) staining will be used on EC tumour cells to identity the presence the location of cell markers phosphorylated Smad2/3 (pSmad2/3), ERK1/2, and PI3K. Anticipated Results: CAF cells are expected to test positive for markers expressed in PDGFRα mediated signalling pathways. Presence of pSmad2/3 is expected to increase over time as usage of the canonical pathway increases in CAF establishment and cancer progression. Non-canonical pathway activation would show levels of ERK2/3 and PI3K. Discussion: pSmad2/3 levels will be examined to determine the usage of the canonical pathway in CAF expansion. Detection of pSmad 2/3 or PI3K/ERK2/3 allows for targeted therapy on the appropriate TGF-ß pathway to block CAF production, thus stopping tumour progression. Suppression of the pathways by targeting specific biomarkers such as PTEN to inhibit mTOR or CAV-1 inhibitors could normalize an upregulated or downregulated TGF-ß pathway. Conclusion: Identifying the key cell markers in the transdifferentiation of NFs allows for the targeting of specific proteins that play a role in the signalling pathways. Standardizing identification of significant cell markers in CAF establishment improves individualized treatment to the cancer patient. Treatment(s) would target the cell markers involved to prevent further CAF proliferation and tumour development